REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, February 21 /PRNewswire/ -- Rosetta Genomics (Nasdaq: ROSG), today announced it will release fourth quarter financial results on February 29, 2007, before the U.S. markets open. Rosetta Genomics will host a conference call with a simultaneous webcast to discuss these results at 8:30 a.m. ET on February 29.
To access the live conference call, U.S. and Canadian participants may dial 1-866-966-5335; international participants may dial +44-20-3023-4460. To access the 24-hour audio replay, U.S. and Canadian participants may dial 1-866-583-1035; international participants may dial +44-20-8196-1996. The access code for the replay is 181543#. The replay will be available until March 7, 2008.
A live audio webcast of the call will also be available on the "Investors" section of the company's website, http://www.RosettaGenomics.com. An archived webcast will be available on the Company's website approximately two hours after the event, and will be archived for 30 days thereafter.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leading molecular diagnostics company developing microRNA-based technologies used in the development of diagnostic tests and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working to develop a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The company expects the first microRNA diagnostic tests based on its technology to be launched during 2008.
Contact: Media: Rachel Spielman, T: +1-212-583-2714, E: media@rosettagenomics.com; Investors: Ron Kamienchick, T: +1-646-509-1893, E: investors@rosettagenomics.com.
Contact: Media: Rachel Spielman, T: +1-212-583-2714, E: media@rosettagenomics.com; Investors: Ron Kamienchick, T: +1-646-509-1893, E: investors@rosettagenomics.com.
Comments